Amol Akhade about the role of CAR-T in solid tumors
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared a post on LinkedIn:
“There is lot of buzz about role of CAR-T in solid tumors .
Nice review published in Nature Biotech. Go through the table showing responses of the recently published data . Note the number of pts in each trial ( some have pts in single digits ) and response rates. No one talks about duration of response. Most needed more than One infusion. Most needed something else along with CAR-T.
Let’s hold our excitement and expectations from CAR-T in solid tumors . It is still more of ” hit or miss ” therapy in solid tumors .
And don’t try it outside clinical trials .
I feel it is just a bubble. Bispecific drugs or may be mRNA Vaccines will win the race over CAR-T.
Remember, we used to do autologous bone marrow transplant for metastatic breast cancer with similar excitement once ( in 1994 )
And we all know where it went from there.”
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023